CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia

EJHaem Pub Date : 2024-12-28 DOI:10.1002/jha2.1076

Rafael Madero-Marroquin, Ryan W. Hunter, Caner Saygin, Hannah Johnston, Adam S. DuVall, Hamed Rahmani Youshanlouei, Clinton Osei, Syed Shah, Wendy Stock, Sandeep Gurbuxani, Anand A. Patel

{"title":"CD58 expression does not impact response to inotuzumab ozogamicin in patients with B-cell acute lymphoblastic leukemia","authors":"Rafael Madero-Marroquin, Ryan W. Hunter, Caner Saygin, Hannah Johnston, Adam S. DuVall, Hamed Rahmani Youshanlouei, Clinton Osei, Syed Shah, Wendy Stock, Sandeep Gurbuxani, Anand A. Patel","doi":"10.1002/jha2.1076","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>CD58 loss has been described as a mechanism of resistance to blinatumomab and chimeric antigen receptor T-cell therapy, functioning as a modulator of response to T-cell activation.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The odds ratio of achieving MRD negativity was 1.03 for every 1000 unit increase in CD58 MFI.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our results suggest that MRD negativity rates after InO are high, regardless of the intensity of CD58 expression.</p>\n </section>\n </div>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11756963/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.1076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

CD58 loss has been described as a mechanism of resistance to blinatumomab and chimeric antigen receptor T-cell therapy, functioning as a modulator of response to T-cell activation.

Methods

Using flow cytometry, we evaluated the impact of CD58 mean fluorescence intensity (MFI) on the probability of achieving measurable residual disease (MRD) negativity in patients with B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin (InO).